ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 78.5 | 90.4 | 54.1 |
| Total income | 78.5 | 90.4 | 54.1 |
| Profit before exceptional items & tax | 6.6 | 6.2 | -1.4 |
| Profit before tax | 6.6 | 6.2 | -1.4 |
| Net profit | 4.9 | 4.7 | -1.3 |
| Operating margin | 8.4% | 6.9% | -2.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +4.30% |
|---|---|
| Revenue, year on year | +45.10% |
BSE results filing, NSE: ENNATURE. Figures extracted from the filing.
Ennature Bio Pharma Ltd: key numbers
- Share price
- ₹196.95
- Market cap
- ₹440.0 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.00 Cr
- Promoter holding
- 59.63%
- FII holding
- 2.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ennature Bio Pharma Ltd
All →Ennature Bio Pharma Other Announcement
Ennature Bio Pharma designated five senior managers (Heads/DGMs) as SMP per SEBI circular. This is a routine compliance intimation with no material business impact.
Ennature Bio Pharma Board Meeting Outcome
Ennature Bio Pharma's board approved adoption of new Articles of Association to align with SCRA Rules 1957 and group governance. The change is subject to shareholder approval.
Ennature Bio Pharma Board Meeting Date
Ennature Bio Pharma will hold a board meeting on 12 November 2026 to consider unaudited second-quarter results ended September 2026. Trading window stays closed until 14 November.
Ennature Bio Pharma Capital Structure Change
Ennature Bio Pharma listed its equity shares on NSE and BSE on 4 November 2026. The company brings its API, biopolymer and nutraceutical businesses to public markets.